tbuckley/cabot-search huggingface dataset:
Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer
Authors: E. Van Cutsem, K. Lesniewski-Kmak, M.P. Saunders, H. Wasan, G. Argiles, C. Borg, G.-J.M. Creemers, M. Fedyanin, R. Glynne-Jones, P. Pfeiffer, C.J.A. Punt, D. Stroyakovskiy, A.J. Ten Tije, A. van de Wouw, V. Cattan, G. Desachy, N. Amellal, V.M. Moiseyenko
Journal: Annals of Oncology (2018)
P2.01-76 The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer
Authors: A. Pattison, L. Jeagal, J. Yeung, A. Pierre, L. Donahoe, M. Cypel, M. De Perrot, K. Yasufuku, G. Darling, T. Waddell, S. Keshavjee, K. Czarnecka-Kujawa
Journal: Journal of Thoracic Oncology (2018)
Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey
Authors: L.O. Kandolf Sekulovic, S.S. Agarwala, A. Hauschild, J. Guo, G.A. McArthur, P. Lorigan, G. Cinat, C. Caglevich, C. Lebbe, P.L. Rutkowski, H. Gogas, R. Dummer, B. Neyns, L. Bastholt, A. Wainstein, D. Herceg, M. Banjin, A. Zhukavets, J. Ocvirk, C. Garbe
Journal: Annals of Oncology (2018)
A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)
Authors: L. Carbognin, I. Sperduti, G. Arpino, M.V. Dieci, F. Schettini, G. Griguolo, M. Brunelli, V. Guarneri, R. Nortilli, E. Fiorio, S. Pilotto, E. Orvieto, E. Manfrin, P. Conte, S. de Placido, G. Scambia, G. Tortora, E. Bria
Journal: Annals of Oncology (2018)
InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial
Authors: S. Rao, F. Sclafani, C. Eng, M. Grønlie Guren, R.A. Adams, A. Benson, D. Sebag-Montefiore, E. Segelov, A. Bryant, C. Peckitt, A. Roy, M.T. Seymour, J. Welch, M.P. Saunders, R. Muirhead, J. Bridgewater, S. Falk, R. Glynne-Jones, D. Arnold, D. Cunningham
Journal: Annals of Oncology (2018)
Identification of patients who benefit from apatinib in advanced gastric cancer: Data derived from a real-world study
Authors: J. Feng, B. Shen, H. Jiang, L. Wang, J. Qian, Y. Shu, P. Chen, G. Mao, B. Liu, X. Zhang, C. Liu, J. Wu, X. Li, W. Cai, W. Shen, Q. Wang, J. He, D. Hua, Z. Zhang, Y. Zhang
Journal: Annals of Oncology (2018)
Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
Authors: P. Terheyden, C. Weishaupt, L. Heinzerling, U. Klinkhardt, J. Krauss, P. Mohr, F. Kiecker, J.C. Becker, A. Dähling (Submitter, F. Döner, R. Heidenreich, B. Scheel, O. Schönborn-Kellenberger, T. Seibel, U. Gnad-Vogt
Journal: Annals of Oncology (2018)
TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC
Authors: P. Christopoulos, M. Kirchner, F. Bozorgmehr, V. Endris, M. Elsayed, N. Magios, A.-L. Volckmar, R. Penzel, F.J.F. Herth, C.P. Heussel, H. Winter, T. Muley, M. Meister, J.R. Fischer, S. Rieken, F. Lasitschka, H. Bischoff, P. Schirmacher, M. Thomas, A. Stenzinger
Journal: Annals of Oncology (2018)
Nomograms predicting survival of patients with advanced or recurrent biliary tract cancer receiving a first-line chemotherapy
Authors: N. Takahara, Y. Nakai, K.O. Saito, M. Sato, H. Ooyama, S. Kanai, T. Suzuki, T. Sato, R. Hakuta, K. Ishigaki, T. Takeda, S. Mizuno, H. Kogure, M. Tada, K. Koike
Journal: Annals of Oncology (2018)
PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial
Authors: J. Trojan, R. Sturgess, D. Harrison Palmer, B. Neu, S. Kasper, A. Dechene, C. Jürgensen, J. Schirra, R. Jakobs, A. Högset, L. Finnesand, H. Olivecrona
Journal: Annals of Oncology (2018)
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Authors: Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang
Journal: Clinical and Molecular Hepatology (2018)

Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9-8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122-8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404-7.228; P=0.47).Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany
Authors: M. De Laurentiis, A. König, K.L. Davis, D. Mitra, C.M.A. Nuzzo, M. Ajmera, S. de Placido, S. Brucker, N. Harbeck
Journal: Annals of Oncology (2018)
MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
Authors: C. Rudin, A. Cervantes, A. Dowlati, B. Besse, B. Ma, D. Costa, P. Schmid, R. Heist, V. Villaflor, I. Sarkar, G. Hernandez, P. Foster, J. Spahn, C. O'Hear, S. Gettinger
Journal: Journal of Thoracic Oncology (2018)
<i>DUXAP8</i>, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2
Authors: Yifan Lian, Jiebin Yang, Yikai Lian, Chuangxing Xiao, Xuezhen Hu, Hongzhi Xu
Journal: Cancer Communications (2018)

Abstract Background Recent studies highlight pseudogene derived long non‐coding RNAs (lncRNAs) as key regulators of cancer biology. However, few of them have been well characterized in pancreatic cancer. Here, we aimed to identify the association between pseudogene derived lncRNA DUXAP8 and growth of pancreatic cancer cells. Methods We screened for pseudogene derived lncRNAs associated with human pancreatic cancer by comparative analysis of three independent datasets from GEO. Quantitative real‐time reverse transcription polymerase chain reaction was used to assess the relative expression of DUXAP8 in pancreatic cancer tissues and cells. Loss‐of‐function approaches were used to investigate the potential functional roles of DUXAP8 in pancreatic cancer cell proliferation and apoptosis in vitro and in vivo. RNA immunoprecipitation, chromosome immunoprecipitation assay and rescue experiments were performed to analyze the association of DUXAP8 with target proteins and genes in pancreatic cancer cells. Results Pancreatic cancer tissues had significantly higher DUXAP8 levels than paired adjacent normal tissues. High DUXAP8 expression was associated with a larger tumor size, advanced pathological stage and shorter overall survival of pancreatic cancer patients. Moreover, silencing DUXAP8 expression by siRNA or shRNA inhibited pancreatic cancer cell proliferation and promoted apoptosis in vitro and in vivo. Mechanistic analyses indicated that DUXAP8 regulates PC cell proliferation partly through downregulation of tumor suppressor CDKN1A and KLF2 expression. Conclusion Our results suggest that tumor expression of pseudogene derived lncRNA DUXAP8 plays an important role in pancreatic cancer progression. DUXAP8 may serve as a candidate biomarker and represent a novel therapeutic target of pancreatic cancer.
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Authors: Michaël Cerezo, Ramdane Guemiri, Sabine Druillennec, Isabelle Girault, Hélène Malka-Mahieu, Shensi Shen, Delphine Allard, Sylvain Martineau, Caroline Welsch, Sandrine Agoussi, Charlène Estrada, Julien Adam, Cristina Libenciuc, Emilie Routier, Séverine Roy, Laurent Désaubry, Alexander M. Eggermont, Nahum Sonenberg, Jean Yves Scoazec, Alain Eychène, Stéphan Vagner, Caroline Robert
Journal: Nature Medicine (2018)
Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy
Authors: H. Mehanna, A. Kong, A. Hartley, P. Mistry, M. Dalby, T. Fulton-Lieuw, M. Robinson, A. Gray, B. Foran, M. Sen, L. O'Toole, K. Dyker, H. Al Booz, R. Moleron, S. Brennan, E. Aynsley, A. Chan, D. Srinivasan, J. Buter, J. Dunn
Journal: Annals of Oncology (2018)
P3.03-28 LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer
Authors: P. Sitthideatphaiboon, A. Cobo, A. Poteete, F. Zhang, D. Lui, W. Rinsurongkawong, J. Heymach
Journal: Journal of Thoracic Oncology (2018)
A phase III study of adjuvant docetaxel, capecitabine and oxaliplatin triplet vs capecitabine and oxaliplatin doublet in patients with curatively resected stage IIIB or IV(M0) (AJCC 6th ed) gastric adenocarcinoma (TRIUMPH, KCSG ST14-05)
Authors: M.-H. Ryu, D.Y. Zang, K.-W. Lee, B.Y. Shim, M.H. Lee, S.Y. Rha, Y.-K. Kang
Journal: Annals of Oncology (2018)
Wood Smoke Exposure Alters Human Inflammatory Responses to Viral Infection in a Sex-Specific Manner. A Randomized, Placebo-controlled Study
Authors: Meghan E. Rebuli, Adam M. Speen, Elizabeth M. Martin, Kezia A. Addo, Erica A. Pawlak, Ellen Glista-Baker, Carole Robinette, Haibo Zhou, Terry L. Noah, Ilona Jaspers
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Exposure to particulates from burning biomass is an increasing global health issue. Burning biomass, including wood smoke, is associated with increased lower respiratory infections.To determine whether acute exposure to wood smoke modifies nasal inflammatory responses to influenza.Healthy young adults (n = 39) were randomized to a 2-hour controlled chamber exposure to wood smoke, where exposure levels were controlled to particulate number (wood smoke particles [WSP]; 500 μg/cm3) or filtered air, followed by nasal inoculation with a vaccine dose of live attenuated influenza virus (LAIV). Nasal lavage was performed before exposure (Day 0) and on Days 1 and 2 after exposure. Nasal lavage fluid cells were analyzed for inflammatory gene expression profiles, and cell-free fluid was assayed for cytokines.Only IP-10 protein levels were affected, suppressed, by WSP exposure in aggregate analysis. Subsequent analysis indicated an exposure × sex interaction, prompting additional analyses of WSP- and LAIV-induced changes in males and females. Inflammation-related gene expression profiles differed between the sexes, at baseline (males greater than females), after LAIV inoculation (females greater than males), and after WSP exposure (increase in males and decrease in females), demonstrating that WSP- and LAIV-induced changes in antiviral defense responses in the nasal mucosa occur in a sex-specific manner.WSP exposure resulted in minimal modification of LAIV-induced responses in aggregate analysis. In contrast, analyzing WSP-induced modification of LAIV responses in the sexes separately unmasked sex-specific differences in response to exposure. These data highlight the need for additional studies to understand sex-specific pollutant-induced effects. Clinical trial registered with www.clinicaltrials.gov (NCT02183753).
P1.03-16 Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer via Blocking CCL2 Expression
Authors: J. Lu, H. Zhong, T. Chu, X. Zhang, R. Li, J. Sun, R. Zhong, Y. Yang, M.S. Alam, Y. Lou, J. Xu, Y. Zhang, J. Wu, X. Li, X. Zhao, K. Li, L. Lu, B. Han
Journal: Journal of Thoracic Oncology (2018)
P1.17-17 The Impact of Induction Chemoradiotherapy Followed by Surgery for N1 Involved Non-Small Cell Lung Cancer
Authors: Y. Takahashi, J. Soh, S. Miyauchi, K. Araki, A. Miura, E. Kurihara, Y. Ogoshi, K. Shien, H. Yamamoto, S. Sugimoto, M. Yamane, K. Kiura, S. Kanazawa, S. Toyooka
Journal: Journal of Thoracic Oncology (2018)
P1.16-61 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Interim Analysis of Randomized Clinical Trial
Authors: S. Yan, Y. Wang, X. Wang, S. Li, C. Lv, Y. Wang, J. Wang, Y. Yang, W. Nan
Journal: Journal of Thoracic Oncology (2018)
Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis
Authors: Nicholas A. Scott, Anna Andrusaite, Peter Andersen, Melissa Lawson, Cristina Alcon-Giner, Charlotte Leclaire, Shabhonam Caim, Gwenaelle Le Gall, Tovah Shaw, James P. R. Connolly, Andrew J. Roe, Hannah Wessel, Alberto Bravo-Blas, Carolyn A. Thomson, Verena Kästele, Ping Wang, Daniel A. Peterson, Allison Bancroft, Xuhang Li, Richard Grencis, Allan McI Mowat, Lindsay J. Hall, Mark A. Travis, Simon W. F. Milling, Elizabeth R. Mann
Journal: Science Translational Medicine (2018)

Macrophages in the healthy intestine are highly specialized and usually respond to the gut microbiota without provoking an inflammatory response. A breakdown in this tolerance leads to inflammatory bowel disease (IBD), but the mechanisms by which intestinal macrophages normally become conditioned to promote microbial tolerance are unclear. Strong epidemiological evidence linking disruption of the gut microbiota by antibiotic use early in life to IBD indicates an important role for the gut microbiota in modulating intestinal immunity. Here, we show that antibiotic use causes intestinal macrophages to become hyperresponsive to bacterial stimulation, producing excess inflammatory cytokines. Re-exposure of antibiotic-treated mice to conventional microbiota induced a long-term, macrophage-dependent increase in inflammatory T helper 1 (TH1) responses in the colon and sustained dysbiosis. The consequences of this dysregulated macrophage activity for T cell function were demonstrated by increased susceptibility to infections requiring TH17 and TH2 responses for clearance (bacterial Citrobacter rodentium and helminth Trichuris muris infections), corresponding with increased inflammation. Short-chain fatty acids (SCFAs) were depleted during antibiotic administration; supplementation of antibiotics with the SCFA butyrate restored the characteristic hyporesponsiveness of intestinal macrophages and prevented T cell dysfunction. Butyrate altered the metabolic behavior of macrophages to increase oxidative phosphorylation and also promoted alternative macrophage activation. In summary, the gut microbiota is essential to maintain macrophage-dependent intestinal immune homeostasis, mediated by SCFA-dependent pathways. Oral antibiotics disrupt this process to promote sustained T cell-mediated dysfunction and increased susceptibility to infections, highlighting important implications of repeated broad-spectrum antibiotic use.
P2.04-11 An IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC
Authors: F. Passiglia, A. Russo, S. Ferro, L. Lalli, A. Cova, H. Soto Parra, L. Rivoltini, V. Huber
Journal: Journal of Thoracic Oncology (2018)
MA26.06 Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative
Authors: E. Thunnissen, B. Lissenberg-Witte, M. Van Den Heuvel, K. Monkhorst, B. Skov, J. Sorensen, A. Mellemgaard, A. Dingemans, E. Speel, J. De Langen, S. Hashemi, I. Bahce, M. Van Der Drift, R. Büttner, M. Looijen Salomon, J. Gosney, P.E. Postmus, S. Samii, F. Duplaquet, B. Weynand, X. Durando, F. Penault-Llorca, S. Finn, B. Oz, N. Akyurek, J. Wolf, L. Bubendorf, A. Hiemstra, S. Duin, I. Marondel, W. Timens, E. Schuuring, P. Pauwels, E. Smit
Journal: Journal of Thoracic Oncology (2018)
P1.01-37 BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study
Authors: X. Hu, X. Zheng, H. Mo, X. Cui, L. Ding, F. Tan, P. Hu, Y. Shi
Journal: Journal of Thoracic Oncology (2018)
Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
Authors: B. van Veggel, A. van der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E.F. Smit, E. Schuuring, J. De Langen
Journal: Annals of Oncology (2018)
MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma
Authors: G. Ceresoli, J. Aerts, J. Madrzak, R. Dziadziuszko, R. Ramlau, S. Cedres, B. Hiddinga, J. Van Meerbeeck, M. Mencoboni, D. Planchard, A. Chella, L. Crinò, M. Krzakowski, F. Grosso
Journal: Journal of Thoracic Oncology (2018)
Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment
Authors: J. Wiskemann, C. Titz, M. Schmidt, K. Steindorf, C. Ulrich, F.J.F. Herth, C.P. Heussel, H. Winter, M. Steins, S. Hummler, M. Thomas
Journal: Annals of Oncology (2018)
Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis
Authors: T. Buchler, O. Fiala, V. Veskrnova, R. Chloupkova, A. Poprach, I. Kiss, K. Kopeckova, L. Dusek, L. Slavicek, M. Kohoutek, J. Finek, M. Svoboda, J. Dvorak, L.B. Petruzelka, B. Melichar
Journal: Annals of Oncology (2018)
P2.11-27 A Rapid Access Lung Cancer Clinic Reduces Variation in Lung Cancer Diagnostic and Treatment Services.
Authors: T. Sibanda, C. Prabhakar, F. Honeyball, K. Thuraisingam, K. Turley, J. Begnell, R. Zielinski, S. Mallwathantri
Journal: Journal of Thoracic Oncology (2018)
Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Authors: R. Plummer, N. Cook, T. Arkenau, J. Melear, C. Redfern, A.I. Spira, K. Chung, T. Haddad, S.S. Ramalingam, R. Wesolowski, E. Dean, T. Goddemeier, M. Falk, G. Shapiro
Journal: Annals of Oncology (2018)
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
Authors: C. Domblides, I. Monnet, J. Mazieres, F. Barlesi, V. Gounant, S. Baldacci, B. Mennecier, A.C. Toffart, C. Audigier Valette, L. Doucet, E. Giroux-Leprieur, F. Guisier, O. Molinier, M. Perol, E. Pichon, G. Robinet, D. Templement Grangerat, A.-M. Ruppert, M. Wislez
Journal: Annals of Oncology (2018)
P1.03-34 Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI
Authors: Y. Zhang, Q. Zhou, Z. Chen, C. Xu, J.-. Yang, X. Zhang, X. Bai, H. Yan, W.-. Li, S. Chuai, J. Ye, H. Zhang-Han, Z. Zhang, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
Erratum: Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Authors: James J Morrow, Ian Bayles, Alister P W Funnell, Tyler E Miller, Alina Saiakhova, Michael M Lizardo, Cynthia F Bartels, Maaike Y Kapteijn, Stevephen Hung, Arnulfo Mendoza, Gursimran Dhillon, Daniel R Chee, Jay T Myers, Frederick Allen, Marco Gambarotti, Alberto Righi, Analisa DiFeo, Brian P Rubin, Alex Y Huang, Paul S Meltzer, Lee J Helman, Piero Picci, Henri H Versteeg, John A Stamatoyannopoulos, Chand Khanna, Peter C Scacheri
Journal: Nature Medicine (2018)
P1.16-35 Sleeve Lobectomy Versus Pneumonectomy for Non-Small Cell Lung Cancer, a Cumulative Updated Meta-Analysis
Authors: Z. Guo, X. Chen, H. Pan, W. Liang, J. He, Y. Hu, F. Wang, D. He, W. Yin, J. He
Journal: Journal of Thoracic Oncology (2018)
A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX)
Authors: K. Chin, A. Takashima, K. Minashi, S. Kadowaki, T. Nishina, T.E. Nakajima, K. Amagai, N. Machida, M. Gotoh, K. Taku, N. Ishizuka, D. Takahari
Journal: Annals of Oncology (2018)
Influenza A(H3N2) Variant Virus Outbreak at Three Fairs — Maryland, 2017
Authors: Monique M. Duwell, David Blythe, Michael W. Radebaugh, Erin M. Kough, Brian Bachaus, David A. Crum, Keith A. Perkins, Lenee Blanton, C. Todd Davis, Yunho Jang, Amy Vincent, Jennifer Chang, Dianna E. Abney, Lisa Gudmundson, Meenakshi G. Brewster, Larry Polsky, David C. Rose, Katherine A. Feldman
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

On September 17, 2017, the Maryland Department of Agriculture (MDA) was notified by fair and 4-H officials of ill swine at agricultural fair A, held September 14-17. That day, investigation of the 107 swine at fair A revealed five swine with fever and signs of upper respiratory tract illness. All five respiratory specimens collected from these swine tested positive for influenza A virus at the MDA Animal Health Laboratory, and influenza A(H3N2) virus was confirmed in all specimens by the U.S. Department of Agriculture National Veterinary Services Laboratory (NVSL). On September 18, MDA was notified by fair and 4-H officials that swine exhibitors were also ill. MDA alerted the Maryland Department of Health (MDH). A joint investigation with MDH and the local health department was started and later broadened to Maryland agricultural fairs B (September 13-17) and C (September 15-23). In total, 76 persons underwent testing for variant influenza, and influenza A(H3N2) variant (A(H3N2)v) virus infection was identified in 40 patients with exposure to swine at these fairs (Figure), including 30 (75%) who had more than one characteristic putting them at high risk for serious influenza complications; 24 (60%) of these were children aged <5 years. Twenty-six (65%) patients reported direct contact with swine (i.e., touching swine or swine enclosure), but 14 (35%) reported only indirect contact (e.g., walking through a swine barn). Two children required hospitalization; all patients recovered. This outbreak highlights the risk, particularly among children, for contracting variant influenza virus at agricultural fairs after direct or indirect swine contact. Publicizing CDC's recommendation that persons at high risk for serious influenza complications avoid pigs and swine barns might help prevent future variant influenza outbreaks among vulnerable groups (1).
Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment
Authors: D.G. Robbrecht, R.J. van Soest, I.F. Tannock, S. Oudard, B. Tombal, M. Eisenberger, F. Mercier, R. de Wit
Journal: Annals of Oncology (2018)
EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
Authors: J.E. Rosenberg, A. Balar, P.H. O’Donnell, E.I. Heath, N.M. Hahn, N.M. Cavazos, A. Melhem-Bertrandt, D.P. Petrylak
Journal: Annals of Oncology (2018)
Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma
Authors: P. Bossi, S. Schmitz, J.-P. Machiels, L.F. Licitra, C. Fortpied Lefevre, C. Caballero, S. Canevari, L. De Cecco
Journal: Annals of Oncology (2018)